Ranbaxy has agreed to a settlement with the US Food and Drug Administration (USFDA) and will make a $500 million provision in relation to a Department of Justice (DoJ) probe to resolve a dispute about plant violations.
Ranbaxy Laboratories Ltd. has signed a consent decree with the U.S. Food and Drug Administration (FDA). Ranbaxy has committed to further strengthen procedures and policies to ensure data integrity. It has also agreed to comply with current good manufacturing practices. The company says that the consent decree is subject to approval by the US District Court for the District of Maryland.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: